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ABSTRACT 
 
Background 
Ventilator-Associated Pneumonia (VAP) is a hospital acquired infection, not present or 
incubating at the time of admission and developing in patients during the process of care within 
the hospital setting. Between nine and twenty-seven percent of patients who are mechanically 
ventilated will develop ventilator-associated pneumonia. Mortality rates for ventilated patients 
who develop ventilator-associated pneumonia are estimated to be between 33-50%. The Institute 
for Healthcare Improvements (IHI) in 2006 recommended the use of ‘care bundles’ to reduce 
VAP but no statistically significant decline has been noted.  
 
Despite the completion of an extensive literature search for purposes of this review, no statistical 
data on nosocomial infections or nosocomial pneumonia relevant to South Africa was found. 
Mechanical ventilation, a support therapy used in approximately one third of patients, 
significantly increases the patient’s risk of developing this nosocomial pneumonia. Critically ill 
patients are by virtue of their critical illness more prone to the development of infections, 
especially ventilator-associated pneumonia. Consistent evidence suggests that oropharyngeal 
colonization can be associated with the development of VAP. Studies focusing on standard oral 
care, with or without the concurrent use of chlorhexidine, have not provided sufficient evidence 
for the use of chlorhexidine in VAP prevention. Chlorhexidine is an antiseptic agent, which 
when tested, proved to reduce total respiratory tract infections by up to 69% (DeRiso et al, 
1996:1558). 
Objective: The aim of this study was to systematically appraise and review evidence on the 
effectiveness of chlorhexidine in reducing the incidence of ventilator-associated pneumonia in 
adult patients. The secondary aim was to systematically summarize evidence on the use of 
chlorhexidine in reducing mortality. 
Methodology: An extensive literature search of studies published in English was undertaken. 
Electronic databases searched were CENTRAL, CINAHL, EMBASE and MEDLINE. Reference 
lists of articles, textbooks and conference summaries were examined. Literature searches were 
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conducted using Medical Subject Headings (MeSH). These included: Ventilator-associated 
pneumonia, chlorhexidine, VAP and oral care. Eight randomized controlled trials, investigating  
the efficacy of Chlorhexidine in ventilator-associated pneumonia prevention in adults met the 
inclusion criteria. The effect measure of choice was Risk ratio with 95% confidence intervals for 
dichotomous data using the random effects (Mantel-Haenszel) model; (p=value of 0.05). 
Heterogeneity was assessed using the Cochrane Q statistic and I².  
Results: Eight randomized controlled trials met the inclusion criteria for this review. Pooled risk 
ratio for the incidence of ventilator-associated pneumonia was 0.64 (95% CI; 0.44-0.91; p 
=0.18). Treatment with chlorhexidine decreased the risk of ventilator-associated pneumonia by 
36%. There was no evidence of Chlorhexidine reducing mortality. 
Conclusions: Chlorhexidine is a cost effective safe treatment in the prevention of VAP. The use 
of 2% chlorhexidine may be more effective in reducing the incidence of VAP. No studies were 
found conducted in developing countries. More rigorously designed trials using 2% 
chlorhexidine are recommended. 
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OPSOMMING 
 
Agtergrond  
Ventilator-Geassosieerde Longontsteking (VAP) is 'n hospitaal verkry infeksie, nie teenwoordig 
met toelating nie. Ventilator-geassosieerde longontsteking word ontwikkel in pasiënte tydens die 
proses van sorg in die hospitaal. Tussen nege en sewe en twintig persent van pasiënte wat 
meganies geventileer word kry ventilator-geassosieerde pneumonie. Sterftesyfers vir 
geventileerde pasiënte wat ventilator-geassosieerde pneumonie ontwikkel is na raming tussen 33-
50%. Die Institute for Healthcare Improvements (IHI) het in 2006 die gebruik van 'sorg bundels' 
aanbeveel om VAP te verminder, maar geen statisties beduidende daling is aangeteken nie.  
Ten spyte van 'n uitgebreide literatuur soek, is geen statistiese data op nosokomiale infeksies of 
nosokomiale longontsteking toepaslik tot Suid-Afrika gevind nie. Meganiese ventilasie, 'n 
ondersteuningsterapie wat gebruik word in ongeveer een derde van die pasiënte, verhoog 
aansienlik die pasiënt se risiko vir die ontwikkeling van hierdie nosokomiale longontsteking. 
Kritiek siek pasiënte is op gronde van hul kritieke toestand meer geneig tot die ontwikkeling van 
infeksies, veral ventilator-geassosieerde pneumonie. Konsekwente bewyse dui daarop dat 
orofaringeale kolonisasie kan met die ontwikkeling van VAP geassosieer word. Studies wat 
fokus op standaard mond sorg, met of sonder die gelyktydige gebruik van chlorhexidine, het nie 
voldoende bewyse vir die gebruik van chlorhexidine in VAP voorkoming nie. Chlorhexidine is 'n 
antiseptiese agent, wat wanneer in een verewekansigde gekontroleerde studies (VGS) getoets 
was die totale respiratoriese kanaal infeksies verminder deur tot 69%.  
Doel: Die doel van hierdie sistematiese literatuuroorsig was om stelselmatig te evalueer en 
bewyse oor die effektiwiteit van chlorhexidine in die vermindering en voorkoms van ventilator-
geassosieerde pneumonie in volwasse pasiënte te hersien. Die sekondêre doel was om 
stelselmatig bewyse op te som op die gebruik van chlorhexidine in die vermindering van sterfte.  
Metodiek: 'n Uitgebreide literatuursoektog van studies wat in Engels gepubliseer is was 
onderneem. CENTRAL, CINAHL, EMBASE en MEDLINE was deursoek. Naslaanlyste van 
artikels, handboeke en konferensie opsommings is ondersoek. Die literatuur soektog is uitgevoer 
met behulp van Medical Subject Headings (MeSH). Dit sluit in: ventilator-geassosieerde 
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pneumonie, chlorhexidine, VAP en mond sorg. Agt verewekansigde gekontroleerde studies 
(VGS), wat die doeltreffendheid van Chlorhexidine in ventilator-geassosieerde pneumonie 
voorkoming in volwassenes ondersoek, was ingesluit vir hierdie studie. Die effek mate van keuse 
was risiko ratio (RR) met 95% vertrouensintervalle met behulp van die ewekansige effekte 
(Mantel-Haenszel) model; (p = 0.05). Heterogeniteit is bepaal deur gebruik te maak van die 
Cochrane Q- statistiek en I².  
Hoof resultate: Agt verewekansigde gekontroleerde studies (VGS) het die insluiting kriteria vir 
hierdie oorsig gepas. Gepoelde risiko ratio vir die voorkoms van ventilator-geassosieerde 
pneumonie: Risiko Ratio (RR) was 0.64 (95% CI; 0.44-0.91; p=0.18). 
Gevolgtrekkings: Behandeling met chlorhexidine het die risiko van ventilator-geassosieerde 
pneumonie met 36% gedaal. Daar was geen bewyse van Chlorhexidine op die vermindering van 
mortaliteit nie. Chlorhexidine is 'n koste-effektiewe veilige behandeling in die voorkoming van 
VAP. Die gebruik van 2% chlorhexidine kan moontlik meer effektief wees in die vermindering 
van die voorkoms van VAP. Meer streng ontwerp studies met 2% chlorhexidine word aanbeveel.  
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CHLORHEXIDINE IN THE PREVENTION OF VENTILATOR 
ASSOCIATED PNEUMONIA: A SYSTEMATIC REVIEW 
 
Olivia Snyders 
Oswell Khondowe  
Janet Bell 
 
Abstract 
Purpose: The aim of this review was to evaluate the evidence on the effectiveness of 
Chlorhexidine in the prevention of Ventilator-associated pneumonia (VAP) in critically ill, adult 
patients. 
Methodology: An extensive literature search of studies published in English was undertaken 
between June 2010 and June 2011. Electronic Databases searched were CENTRAL, CINAHL, 
EMBASE and MEDLINE. Reference lists of articles, textbooks and conference summaries were 
examined and hand searching was performed. Literature searches were done by use of Medical 
Subject Headings (MeSH) terms, these included: Ventilator-associated pneumonia, 
chlorhexidine, VAP and oral care.  
 Selection Criteria: Eight randomized controlled trials, investigating the efficacy of 
Chlorhexidine in ventilator-associated pneumonia prevention in adults met the inclusion criteria.  
Analysis: Data on ventilator-associated pneumonia was extracted as dichotomous variables. The 
effect measure of choice was Risk ratio with 95% confidence intervals for dichotomous data 
using the random effects (Mantel-Haenszel) model; (p=value of 0.05). Heterogeneity was 
assessed using the Cochrane Q statistic and I².  
Results: Eight randomized controlled trials met the inclusion criteria for this review. Pooled risk 
ratio for the incidence of ventilator-associated pneumonia was 0.64 (95% CI; 0.44-0.91; p = 
0.18). 
 
Conclusion: Treatment with chlorhexidine decreased the risk of ventilator-associated pneumonia 
by 36%. There was no evidence of effect of chlorhexidine on mortality. 
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INTRODUCTION 
Background 
Ventilator-Associated Pneumonia (VAP) is a hospital acquired infection. This infection, which 
was not present or incubating at the time of admission, develops in patients during the process of 
care within the hospital setting (WHO, 2010: N.P).  
 
In 2009, the hospital acquired infection (HAI) burden was reported in the USA as 1.7 million, 
resulting in 99,000 deaths per annum and $26-33 billion in added healthcare costs. Implementing 
evidence-based prevention strategies can result in up to a 70% or greater reduction in HAI’s 
(Healthcare-Associated Infections: State Plans, 2009: N.P). In 2008, the burden of HAI’s in 
Europe was reported as ranging between 3.5-14.8% (average: 7.1%). These infections added an 
extra 16 million days of hospital stay with 37 000 attributable deaths (ECDC, 2008: N.P). When 
considering direct costs alone, the annual economic impact was estimated to be about EUR 7 
billion per year (ECDC, 2008: N.P). Between nine and twenty-seven percent of patients who are 
mechanically ventilated will develop VAP. Mortality rates for those patients who develop VAP 
are high with between 33-50% of ventilated patients developing this condition (American 
Thoracic Society, 2005:390). Despite recommendations by the Institute for Healthcare 
Improvements in 2006 to utilise the bundle methodology to reduce VAP, the incidence of VAP 
has not shown a statistically significant decline. No statistical data on nosocomial infections or 
nosocomial pneumonia relevant to South Africa or developing countries was found following an 
extensive literature search.  
 
Description of the condition 
VAP can occur in critically ill patients who are mechanically ventilated for periods longer than 
48 hours (Augustyn, 2007:32). VAP is associated with the Intensive Care Unit (ICU) setting and 
the pathogenesis involves the entry of bacteria to the patient’s lower respiratory tract and 
overwhelming of the patient’s defences (Powers, 2006:48B).  
 
VAP can be identified in patients presenting with chest radiographic examinations showing new 
or progressive infiltrate, consolidation, cavitations, or pleural effusions. In addition, the patient 
presents with at least one of the following symptoms: new onset of purulent sputum or a change 
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in colour of sputum, increased temperature, increased or decreased white cell count, organisms 
cultured from blood, isolation of an etiological agent obtained by transtracheal aspirate, 
bronchial brushing or biopsy (CDC, 2006). 
 
Hospital-acquired infections/nosocomial infections, and therefore VAP, impact the consumers of 
health care (patients) negatively by providing a gateway for more serious illnesses to develop 
and by prolonging a patient’s stay in a health care facility (WHO, 2010:N.P). Inadvertently this 
can contribute to long term disability and results in a high personal cost to the patient and their 
family (WHO, 2010:N.P). Furthermore ventilator-associated pneumonia contributes to mortality 
within populations and is an additional financial burden to the health care consumer and the 
health care facility (WHO, 2010:N.P). Ventilator-associated pneumonia (VAP) in patients who 
are already critically ill prolongs hospitalization, delays recovery and significantly increases the risk of 
complications and death (Pruitt & William, 2005:36).  
 
Mechanical ventilation is used as a support therapy in approximately one third of patients in 
intensive care units (Munro & Grap, 2004:27). Patients requiring mechanical ventilation are at 
risk of developing ventilator-associated pneumonia (Munro & Grap, 2004:27). The risks 
associated with mechanical ventilation and predisposing patients to ventilator-associated 
pneumonia are: 
• re-intubation 
• self extubation 
• contamination of ventilator circuits  
• poor humidification  
• supine positioning  
• presence / absence of naso-gastric tubes (Morton et al, 2005: 546).  
 
Critically ill patients are immune-compromised by virtue of their critical illness (Munro & Grap, 
2004:27). Consistent evidence suggests that oropharyngeal colonization is the most important 
pathogenic mechanism in the development of VAP and that dental plaque may serve as a 
reservoir for organisms (Pobo et al, 2009:437). Garrouste-Orgeas, Chevret and Arlet, et al, as 
cited by Schleder, (2004:50) concluded in their studies that bacteria may invade the lower 
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respiratory tract by micro- or bolus aspiration of oropharyngeal organism, inhalation of aerosols 
containing bacteria, or haematogenous spread from a distant site (Schleder, 2004:50). Experts 
believe aspiration to be one of most significant causes of hospital acquired pneumonia (Schleder, 
2004:50). Factors identified as leading to nosocomial pneumonia are oropharyngeal colonization, 
gastric colonization, aspiration and compromised lung defences (Morton et al, 2005: 546).  
 
Several strategies have been researched intensively and proposed as key factors in the prevention 
of ventilator- associated pneumonia (IHI, 2006:N.P). VAP is one of the six interventions that the 
Institute for Healthcare Improvement (IHI) included in the 100,000 Lives Campaign, a national 
initiative taken to improve patient care, reduce the prevalence and number of hospital acquired 
infections and improve patient outcomes by the use of ‘Bundles’ (IHI, 2006). Bundles, also 
referred to globally as “care bundles”, are groups of disease-specific interventions which are 
evidence-based and regarded as ‘best’ practices’ (IHI, 2006). Individual practice interventions 
can add to the improvement of the patient but when used collectively, as a ventilator bundle, 
have proven to be most effective in reducing complications associated with ventilation and 
significantly reducing the incidence of VAP in ventilated patients (IHI, 2006). 
 
The interventions in the VAP prevention bundle include elevation of the head of bed (HOB) to 
between 30 and 45 degrees, deep vein thrombosis (DVT) prophylaxis, daily ‘sedation vacations’ 
or assessment of readiness to extubate and peptic ulcer disease (PUD) prophylaxis (IHI, 
2006:N.P). Oral care was not emphasized as a crucial component of the ventilator bundle. In 
2010, the AACN issued a practice alert as a recommendation and guideline to nurses 
emphasising the benefits of oral care and focused specifically on oral care within mechanically 
ventilated patients. Amongst several studies done to prove the importance of oral care in 
mechanically ventilated patients, Mori, Hirasawa, et al concluded in their study that oral care 
decreased the incidence of VAP in ICU patients (Mori et al, (2006:230). 
 
Dental plaque is a reservoir for pathogens (Heo, Haase, Less, Gill, & Scannapieco, 2008:1568).  
Several organisms which primarily colonize dental plaque are present in nasal and oral secretions 
(Augustyn, 2007:33).  Aspiration of bacteria containing secretions, from the oro-pharynx to the 
lungs, can lead to the development of chest infections (Heo, Haase, Less, Gill, & Scannapieco, 
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2008:1568). Entry routes for these organisms to the lungs are by micro-aspiration of bacteria 
laden secretions, which pool above the endotracheal cuff of intubated patients (Augustyn, 
2007:33). This leads to colonization of the respiratory tract (Augustyn, 2007:33).   
Risk factors contributing to the development of VAP are:  
• a decreased level of consciousness  
• patients’ body position  
• underlying medical conditions  
• the presence of an endotracheal tube  
• ventilator circuits  
• naso-gastric/oro-gastric tubes 
• poor infection control practices by staff (Augustyn, 2007:33). 
The American Association of Critical Care Nurses (AACN), in recognition of the lack of nursing 
guidelines or protocols for the prevention of ventilator –associated pneumonia, in 2008 issued a 
practice alert (AACN, 2008:N.P.). This practice alert would guide critical care nurses as to the 
proven strategies to prevent VAP in mechanically ventilated patients (AACN, 2008:N.P.).  
 
How chlorhexidine might work 
Fourrier et al (2005:1732) confirmed findings of a high level of concordance between bacteria 
isolated from dental plaque and those found in the lung. Sequential sampling of dental plaque 
from ICU patients showed that more than 50% of patients acquiring a respiratory infection are 
previously colonized at the gingivodental level by the same pathogens (Fourrier et al, 
2005:1732). Fourrier et al, (2005:1733) state that teeth should be considered a substantial 
reservoir for respiratory pathogens of which decontamination of the oropharynx with the use of 
antiseptic solutions could reduce the incidence of acquired respiratory infections. 
 
Chlorhexidine is a cationic chlorophenyl bis-biguanide antiseptic agent. Chlorhexidine has been 
used as an oral disinfectant in mechanically ventilated patients because of its ability to bind to 
oral tissues with subsequent slow release of antiseptic properties and thus a long period of anti-
bacterial action (Scannapieco et al, 2009:2). The trial by DeRiso et al (1996), reported findings 
of a 69% reduction in the total respiratory tract infections within their chlorhexidine treated 
group (DeRiso et al, 1996:1558). In a literature review, O'Reilly (2003:108) demonstrated that 
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using chlorhexidine as an adjunct to mechanical plaque removal suppresses the colonization of 
dental plaque by potential pathogens.   
 
Poor oral hygiene and exposure of the oral cavity can compromise the immune components of 
saliva (Munro & Grap, 2009:429). Saliva contains a wide variety of specific and innate immune 
components and as it circulates in the oral cavity, provides a form of mechanical removal of 
plaque and microorganisms (Munro & Grap, 2004:27). A reduction in the amount of saliva leads 
to microbial overgrowth in the oropharynx, followed by dental plaque accumulation and the 
development of dental caries (Munro & Grap, 2004:27). Exposed oropharyngeal and 
nasopharyngeal cavities may lead to a dry mouth, also known as xerostomia (Munro & Grap, 
2004:27).  The majority of mechanically ventilated patients may have equipment or devices, 
such as endotracheal tubes in place which keep the oropharyngeal and nasopharyngeal cavities 
continuously open. Other contributors to the development of xerostomia in critically ill patients 
are:  
• Psychological factors such as anxiety and stress 
• Pharmacological agents, physiological contributors such as dehydration associated with 
fluid imbalances  
• Underlying diseases such as Sjogren syndrome.  
Once xerostomia develops, dental plaque accumulates reducing the amount of salivary immune 
factors within the oral cavity. Powers (2006:48D) states that micro aspiration of bacteria from 
the oropharyngeal cavity can precipitate the development of VAP. 
 
Significance of this research  
Historically dental plaque and associated microbes are removed using two known methods: 
mechanical interventions (including tooth brushing and rinsing of the oral cavity) and 
pharmacological interventions (including use of antiseptic and antimicrobial agents).  
Studies focusing on standard oral care, with or without the concurrent use of chlorhexidine, have 
not provided sufficient evidence for the use of chlorhexidine in VAP prevention. Although VAP 
prevention requires a multi-disciplinary and multi-faceted approach, oral care is primarily a 
nursing led intervention. Oral care has not been sufficiently focused on as a part of VAP 
Stellenbosch University  http://scholar.sun.ac.za
7 
 
prevention. Nursing research, protocols and interventions to prevent ventilator-associated 
pneumonia are lacking. 
 
Aims: 
The primary aim of this study was to systematically appraise and review evidence on the 
effectiveness of chlorhexidine in reducing the incidence of ventilator-associated pneumonia in 
adult patients. The secondary aim was to systematically summarize evidence on the use of 
chlorhexidine in reducing mortality. 
 
Criteria for selection of studies: 
Inclusion Criteria 
Types of studies:  
General eligibility criteria for articles required that the studies were: 
• Published in English  
• Randomized controlled trials or quasi-experimental studies using comparative groups 
• Investigating chlorhexidine as an oral decontaminant in the prevention of VAP  
Types of interventions: Studies were included if they investigated the use of chlorhexidine 
versus tooth brushing, placebo or other comparators as oral care interventions to reduce VAP in 
adult mechanically ventilated patients. Studies included therefore had to have an experimental or 
treatment group with chlorhexidine and a comparative without chlorhexidine. 
Types of participants: The settings for selected studies were intensive care units where 
mechanical ventilation was being performed. Study participants were mechanically ventilated 
adult patients (18 years or older, legally able therefore to provide consent for research purposes), 
with valid consent for study. In the selected studies all participants were 18years and older as the 
studies focused on adult intensive care units. 
Types of outcome measures: The primary outcome of interest was reduction of the incidence of 
VAP in mechanically ventilated adult patients. The secondary outcome was a reduction in 
mortality. 
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Exclusion criteria 
Studies were excluded when VAP was not investigated as an outcome even when chlorhexidine 
was used. Exclusion criteria within the individual included studies were similar. Patients under 
the age of 18 years were excluded. Other exclusion criteria within individual studies were a 
clinical diagnosis of pneumonia at start of study, extubated patients, edentulous patients, patients 
with a known allergy and hypersensitivity to chlorhexidine.  
Exclusion criteria for this review were a high attrition rate of greater than 20%, unavailability of 
the full text article and incomplete study or outcome data within the included studies. 
 
Dealing with missing data: Where pertinent data was missing from the included trials, the 
authors concerned were contacted. Missing data was regarded as the absence of any results 
adding weight to the study, reports on study outcomes or details on methodology applied 
throughout trials.   
 
Methodology 
Search Methods for identification of studies 
Electronic searches 
An extensive literature search of published clinical trials reporting on VAP prevention, with the 
use of chlorhexidine in oral care, was undertaken. Peer-reviewed publications were searched 
between June 2010 and July 2011.  Sources for relevant studies included the following 
databases: the Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative 
Index of Nursing and Allied Health (CINAHL) and MEDLINE from inception to present. 
Literature searches were done by use of Medical Subject Headings (MeSH). The MeSH terms 
used for the search included: Ventilator-associated pneumonia, VAP, chlorhexidine, hospital 
acquired pneumonia, nosocomial infections, mechanically ventilated patients, intensive care, 
mouthwash, mouth care, oral care, oral hygiene and dental care.  In total 73 articles were 
retrieved electronically of which eight of these were trials chosen for inclusion in this systematic 
review. 
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Searching for other resources 
Reference lists of all relevant articles and textbooks were searched for further relevant studies. 
Experts in critical care nursing, critical care medicine, infection control, microbiology and 
dentistry were consulted to identify other studies. Hand searching (pearling) of reference lists of 
all potentially eligible papers (n=8) was performed. Summaries from conference proceeding 
were examined.  
 
Data Collection and Analysis  
Selection of studies 
The above-mentioned search strategies were independently employed by the two reviewers and 
initially the title of the articles were considered. Titles that were relevant to the study were 
identified by searching with the use of the following keywords: ventilator-associated pneumonia, 
chlorhexidine, oral care, mouth care, nosocomial pneumonia.  Irrelevant titles were discarded if 
they never contained any of the search words.  
Thereafter the article abstracts of relevant titles were retrieved and reviewed independently by 
two reviewers with consideration of the inclusion criteria as described in a previous section. Full 
texts of relevant articles meeting the inclusion criteria were obtained, reviewed and analyzed for 
methodological quality. The reviews were conducted independently by the two reviewers, Olivia 
Snyders (OS) and Oswell Khondowe (OK). In case of disagreements not being resolved by 
discussion, the third reviewer Janet Bell (JB) was available for consultation.  
 
Data extraction and management 
Selection of studies: A data extraction tool was developed and utilized to collect information 
from the studies relevant for this review. A pilot study was conducted to determine the feasibility 
of the study and to test the search range, assessment and extraction tools. The data extraction tool 
included baseline characteristics such as study id, citation, methodology, setting, population and 
sample size, loss to follow up (LTFU) and country where the study was conducted. The two 
reviewers (OS and OK) extracted all relevant data from the studies as per the data extraction 
tool.  
Assessment of risk of bias in included studies: Methodological quality was assessed by two 
reviewers (OS & OK) using the Cochrane quality assessment form. The quality assessment form 
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is freely available on the Cochrane website (The Cochrane Collaboration, 2009: N.P.). The 
assessment tool addressed the following elements of randomized controlled trials:  
• External validity ( ability to generalize findings),   
• Internal validity (adequate sequence generation, allocation concealment, blinding of 
participants, incomplete outcome data, selective outcome reporting and other biases).  
Measures of treatment effect: The effect measure of choice was risk ratio with 95% confidence 
intervals for dichotomous data and weighted mean difference using the random effects model 
(Mantel-Haenszel method). The p value was set at 0.05.   
Unit of analysis: All included studies randomized participants to a treatment group or a control 
group. 
Dealing with missing data: Where pertinent data was missing from the included trials, the 
authors concerned were contacted. Missing data was regarded as the absence of any results 
adding weight to the study, reports on study outcomes or details on methodology applied 
throughout trials.   
Assessment of heterogeneity: Pooled effect sizes of risk ratio (RR) were estimated using 
(Mantel-Haenszel) random effects model and 95 % Confidence intervals (CI) were presented. 
Heterogeneity was calculated by use of I² = [Q-df/ Q] x100 %, where Q is the Chi-squared 
statistic and df is its degrees of freedom. This describes the percentage of the variability in effect 
estimates which is due to heterogeneity rather than chance. A value of less than 40 % was 
considered as not important. An I² value of 40 to 60 was considered moderate heterogeneity and 
more than 60 to 75 as substantial heterogeneity. Values of 75% and above were regarded as 
considerable heterogeneity.  
Assessment of reporting biases: Reporting bias was not identified in any of the included 
studies.  
Data synthesis: All relevant data were entered into a statistical analysis software package known 
as Review Manager (version 5.1, Cochrane Collaboration: N.P.) for analyses. The effect measure 
of choice was risk ratio with 95% confidence intervals for dichotomous data and weighted mean 
difference with 95% confidence intervals for continuous data using the random effects (Mantel-
Haenszel) model.  
Studies drawn for inclusion in this systematic review were all different with regard to several 
aspects, i.e. trial settings, varying ages, varying methods of treatment application, etc. These 
Stellenbosch University  http://scholar.sun.ac.za
11 
 
differences could therefore impact the treatment effect, which in this case would vary between 
studies. Using the random effects model allows for the distribution of effect sizes and ultimately 
a combined estimate and the average of a distribution of values. Forest plots were used to 
demonstrate the effect of interventions.        
Subgroup analysis and investigation of heterogeneity: Subgroup analysis was completed on 
trials after identifying clinical diversity. In this systematic review, subgroup analysis was 
conducted with respect to the differing concentrations of chlorhexidine used within these 
included trials.   
Sensitivity analysis: Data was entered into RevMan 5.1. and a sensitivity analysis was 
performed.  
Reliability and Validity: Reliability, validity and quality assessment of study data was ensured 
by piloting and using a standardized data extraction form (The Cochrane Collaboration, 2009: 
N.P.). Both reviewers (OS & OK) performed research tasks independently. They (OS & OK) 
have attended research methodology and systematic review workshops and undergone other 
relevant training. OK has previously conducted and published systematic reviews in peer 
reviewed journals.  
Ethical approval: Ethical approval to conduct this review was obtained from the Health 
Research Ethics Committee at the Stellenbosch University.  
 
RESULTS 
Results of search: The results of the search are shown in Figure 1. Of the 86 titles and abstracts 
identified, 94.2% (81) were from electronic searches and the remaining 5.8% (5) were identified 
from manual reference checks. The reviewers excluded 71 articles because the titles were not 
relevant to the review. After reading the abstracts of the remaining 15 studies, 4 studies were 
excluded for failing to report outcomes as VAP. Full articles were retrieved for the 11 studies 
and appraised for methodological quality. Three articles were excluded following this process. 
Meta-analysis was performed on 8 studies.  
 
Description of selected studies: The studies included in this review (n=8) were all randomized 
controlled trials. The trials collectively enrolled a total of 1930 patients of which 947 received 
chlorhexidine (treatment group) as varying oral formulations. 
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Studies Included: The eight studies included in this review are DeRiso et al (1996), Fourrier et 
al (2000), Fourrier et al (2005), Houston et al (2002), Koeman et al (2006), Pobo et al (2009), 
Scannapieco et al (2009) and Tantipong et al (2007).  
 
Studies excluded: Three studies were excluded after critical appraisal of methodologies (n=3). 
The trial conducted by Munro and Grap et al (2009) was excluded after repeated, unsuccessful 
attempts to contact the authors for information. The full text article of a trial by MacNaughton et 
al (2004) could not be located. The trial by Grap et al (2004) was excluded after the full text 
review revealed an attrition rate of 50%. 
 
Studies Included in review 
Characteristics of included studies (Table 1) 
Trials Settings: All trials were conducted within critical care settings where patients are 
dependent on nursing care to meet their hygiene needs and more specifically, oral care needs 
(See Table 1). These settings included cardiothoracic intensive care units (n=2), trauma intensive 
care units (n=1), medical intensive care units (n=1) and mixed medical-surgical intensive care 
units (n=4). Some studies were single-centre (n=5) focused while others were multi-centre (n=3). 
 
Intervention group: The chlorhexidine preparations varied amongst the experimental groups. 
The majority of the included trials used chlorhexidine in the form of an oral solution. The trial by 
Pobo et al (2009) used chlorhexidine digluconate.  Chlorhexidine digluconate differs from 
chlorhexidine gluconate only on a molecular binding level. This difference is insignificant and 
does not affect the potency or effect of chlorhexidine. Chlorhexidine digluconate was regarded as 
included in the subgroup analysis done on the variance of concentration levels of chlorhexidine.  
Amongst the treatment group variance was noted in the concentrations of the chlorhexidine used. 
The majority of trials used chlorhexidine 0.12% (n=4), while others (n=2) used chlorhexidine 
0.2% and chlorhexidine 2% concentrations (n=2).  
 
Comparison group: The comparison groups received, placebos in the form of oral solution, gel 
or pastes with a similar taste, smell or consistency as the chlorhexidine (n=5). The comparison 
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groups also received power tooth brushing (n=1), normal saline oral rinse (n=1) or phenolic 
rinse, Listerine, (n=1).  
 
Loss to Follow-up: Loss to follow-up was low among the included trials, ranging from 0% to 
16.5%. 
 
Diagnostic criteria: Diagnostic measures used to diagnose ventilator-associated pneumonia 
included semi-quantitative microbiology techniques and quantitative microbiology techniques.  
 
Risk of Bias in included studies (Table 2) 
Methodological assessment: computerized randomization was the most frequently used method 
amongst the trials (n=5). Other means of randomization included block randomization stratified 
by site (n=1), stratified randomization according gender and hospital location (n=1) and 
consecutive randomization by medical record numbers (n=1). Allocation concealment was 
achieved in most of the trials by having pharmacy staff complete the randomization schedule. 
Other methods of allocation concealment included opaque sealed envelopes and web-based 
subject identity number. There was no mention of blinding of participants or allocation 
concealment in the trial by Houston et al (2002).  
 
Results of pooling trials:   
The use of chlorhexidine was supported in the 8 trials with a risk ratio of 0.64 (95% CI; 0.44 - 
0.91; p = 0.18). The pooled results showed evidence of the effectiveness of chlorhexidine in 
reducing ventilator-associated pneumonia, as the test for overall effect is reflected as Z= 2.47 (p= 
0.01). Figure 2 shows a good overlap of confidence intervals although most individual studies 
did not show benefit in the use of chlorhexidine in reducing ventilator-associated pneumonia.  
 
Subgroup analysis: Subgroup analyses were performed on the three common strengths of 
chlorhexidine to determine their effect on the results (Figure 3).  In the chlorhexidine 0.12% 
group, 32 of 574 patients developed VAP associated with a risk ratio of 0.70. In the 
chlorhexidine 0.2% trials, 18 or 144 patients had developed VAP associated with a risk ratio of 
0.62.  
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In the chlorhexidine 2% trials 18 of the 229 patients in the chlorhexidine treatment group were 
found to develop VAP, the risk ratio was 0.53 (95% CI; 0.31-0.91; p = 0.11). Chlorhexidine 2% 
therefore demonstrated a better treatment effect. 
 
Mortality 
Results of all 8 trials were available for pooling and analysis of mortality (Figure 4). DeRiso et 
al, (1996:1559) reported findings of a reduction in mortality within  their chlorhexidine 0.12% 
treatment group, the reduction being 1.16% as compared to 5.56% in the comparison groups. 
These findings are also reflected within the pooled analysis (figure 4) performed for this review. 
Mortality was a secondary outcome of interest when doing this review therefore the effect of 
chlorhexidine on mortality was now explored. In this systematic review, mortality appeared to be 
unaffected by chlorhexidine with a risk ratio of 1.12 (95% CI; 0.86-1.46; p = 0.18). 
 
Cost effectiveness of chlorhexidine:  
Tantipong et al, reported  findings of cost effectiveness with use of chlorhexidine 2%, the mean 
cost per patient calculated to be ten times less than the cost of antibiotics needed to treat an 
episode of VAP (Tantipong et al, 2008:135). Koeman et al (2002:1352) also found chlorhexidine 
to be an extremely cost effective safe intervention in VAP prevention especially when 
considering the absence of known side effects in their trial. 
 
Side effects associated with chlorhexidine use: 
Side effects related to 2% chlorhexidine oral solution use was observed and reported in 9.8% of 
participants in the trial by Tantipong et al, (2008:133). These side effects were reported to be 
mild, reversible and affecting mainly the oral mucosa, observed in 10 of the 102 patients 
randomized to the chlorhexidine treatment group. Tantipong et al, however reported observing 
this irritation after personnel responsible for administering the treatment were found to be 
vigorously rubbing the oropharyngeal mucosa with gauze soaked 2% chlorhexidine (2008:135). 
Personnel were instructed therefore to clean the oropharyngeal mucosa gently, after which the 
incidence of irritation was reduced (Tantipong et al, 2008:135).    
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DISCUSSION  
Eight randomized controlled trials met the inclusion criteria. Using the random effects (Mantel-
Haenszel) model, the pooled risk ratio was 0.64 (95% CI; 0.44 - 0.91; p = 0.18). The probability 
of mechanically ventilated patients acquiring ventilator-associated pneumonia with the use of 
chlorhexidine is 36% less likely than in controls and heterogeneity was not of concern as 
I²=31%. As stated earlier in this review, when assessing heterogeneity an I² value of less than 40 
is considered not important. These findings were consistent with a previous meta-analysis done 
by Chlebicki and Safdar, (2007:598) who found a pooled relative ratio of 0.70 (95% CI; 0.48-
1.04; p = 0.08). 
In another meta-analysis done by Chan et al (2007), pooled analysis of the seven trials that tested 
the effect of antiseptic oral decontamination on ventilator-associated pneumonia showed a 
significant reduction with a relative risk of 0.56 (0.39 to 0.81; p = 0.002; I²=48.2%).  
 
Heterogeneity is a problem inherent in all systematic reviews since it involves the pooling of 
several trials to obtain an overall effect by the combination of trials. Within individual trials 
homogeneity of comparison and treatment groups were satisfactory.  
In this systematic review, individual trial interventions differed, i.e. Different trial settings, 
differing chlorhexidine dosage, concentrations and method of administration of treatments, 
diagnostic criteria and exclusion criteria. Subgroup analysis was performed where these 
differences were observed. Use of random effects model for analysis proved useful also within 
this systematic review by ensuring heterogeneity was adequately addressed. 
In this systematic review, chlorhexidine 0.12% and chlorhexidine 0.2% failed to show any 
significant effect.  
  
However, chlorhexidine 2% demonstrated a more significant effect on the incidence of VAP 
when using a random effects analysis, with a risk ratio 0.53 (95% CI; 0.31-0.91; p = 0.63). There 
was no evidence of heterogeneity in the subgroup analysis of studies that used chlorhexidine 2% 
and results from the overall test of heterogeneity was 0 % (I²= 0%; df =1; p=0.62; Chi²= 0.24). A 
meta-analysis recently undertaken by Labeau, Van de Vyver, Brusselaers, Vogelaers and Blot 
(2011:6), in their subgroup analysis done on the varying concentrations of chlorhexidine, for 
chlorhexidine 2% produced a risk ratio 0.53 (95% CI; 0.31-0.91; p = 0.62). The results for 
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Labeau et al, were identical and consistent with the findings for subgroup analysis done for this 
systematic review. Chlorhexidine 2% may provide a better reduction of VAP within high risk 
patients (those from mixed and medical intensive care units). Ironically chlorhexidine 0.12 % 
and chlorhexidine 0.2% were used in the majority of trials and showed no effect in reducing 
VAP (Figure 3). These results support the use of 2% chlorhexidine versus 0.12% chlorhexidine 
and 0.2% chlorhexidine for reducing VAP. Findings of this study support therefore that 
chlorhexidine 2% may provide a better reduction of VAP within high risk patients (those from 
mixed and medical intensive care units). 
 
Methodological bias could not be overlooked, especially in those trials which we found to be at 
high risk for bias. In terms of adequate sequence generation, the study by Houston et al, (2002) 
was considered high risk because trial participants were randomized by consecutive medical 
record numbers, adding predictability to the randomization process. Houston et al (2002) also 
failed to report on concealment or blinding procedures making the detection of bias difficult and 
therefore marked as ‘unclear’ within the  methodological quality/ risk of bias assessment 
prepared for this systematic review (Table 2). Pobo et al (2009) also was considered high risk for 
methodological bias as that trial was prematurely ended by the steering committee after no 
differences were found between treatment and comparison groups.  
 
In consideration of these methodological concerns, the above-mentioned trials were entered into 
RevMan 5.1 and a sensitivity analysis was completed (Appendices: Figure 5). Sensitivity 
analysis resulted in a more favourable effect of chlorhexidine by overall use in the remaining 
population, with a risk ratio of 0.57 (95% CI; 0.40-0.81; p= 0.39). Chan et al,  in their systematic 
review and meta-analysis showed consistency with this review and previous works emphasizing 
that unblinded designs and trials considered to be of lower methodological quality tend to yield 
greater treatment effects (2007:8).   
 
In the trial by Tantipong et al (2007), randomization was stratified by gender and hospital 
location. Methods of allocation based on patient characteristics such as date of birth or gender, 
are usually not reliably random.  This is due to this method of randomization being predictable 
and not easily concealed, reducing the guarantee that allocation has indeed been random and no 
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potential subjects have been excluded by foreknowledge of the intervention. To strengthen their 
allocation sequence however, Tantipong et al (2007) also randomized by hospital location, 
therefore the study was still regarded as having low risk for bias. 
 
Trial settings within the included studies contributed to heterogeneity of results. The trials which 
had been conducted within cardiothoracic intensive care units had a low incidence of VAP (7 of 
443 in the chlorhexidine groups and 18 of 471 in the comparison group). These observations and 
findings were consistent with those of Chlebicki and Safdar (2007) and Labeau et al (2011) in 
their meta-analyses. One could further argue that because the trials done by DeRiso et al (1996) 
and Houston et al (2002) were performed in cardio-thoracic intensive care units, they achieved 
better effect from the use of chlorhexidine. Cardiac patients, especially those planning to have 
elective surgery, such as valve surgery, generally have a better physiological status and better co-
morbid conditions with the duration of ventilation rarely exceeding 24 to 48 hours. Benefit to the 
participants would therefore be more impressive and significant. Subgroup analysis in this 
review was attempted using the random effects model and pooling data from only these two 
trials revealing a risk ratio of 0.41 (95% CI; 0.17-0.98; p = 0.72).  
 
In the mixed medical populations, the period of ventilation and intubation usually exceeds 24-48 
hours, patients generally have more underlying co-morbidities and multi-medical problems 
making these patients more prone to developing VAP as well as other infections. Length of stay 
together with length of ventilation can be extended due to this. These observations are consistent 
with the rational of Chan, Ruest, Mead and Cook (2007:8) who also found a greater treatment 
effect in the non- medical intensive care settings.  
 
Mortality was unaffected by the use of chlorhexidine with a risk ratio of 1.12 (95% CI; 0.69 – 
1.45; p = 0.18 and I² = 31% indicating moderate clinical heterogeneity. These findings again 
were consistent with recent findings by Chlebicki and Safdar (2007), Chan et al (2007) and 
Labeau et al (2011). Clinical diversity, causing heterogeneity amongst trials, was apparent and 
could be linked again to the lack of effect of chlorhexidine on mortality.  
Heterogeneity therefore may also be directly linked to the effect of chlorhexidine on mortality. 
Mixed ICU patients and medical patients generally tend to have more co-morbidity’s and 
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produce higher figures for mortality. The trial by DeRiso et al, (1996), as an individual trial 
found a reduction on mortality. Again, these findings may have been directly related to the 
underlying heterogeneity associated with trial setting and the risks for mortality being lower 
within the cardio-thoracic populations. 
A formal cost analysis of chlorhexidine was not yet undertaken but individual trials have 
reported chlorhexidine to be a cost-effective alternative in comparison to the cost of treating an 
episode of VAP, or in comparison to the use of prophylactic antibiotic therapy. Side effects were 
minimal within the individual trials included in this meta-analysis therefore chlorhexidine may 
prove to be a safer alternative to prophylactic antibiotics.    
 
Summary of main results 
Eight studies included in this review contributed to overall completeness of this systematic 
review. This review was conducted thoroughly and effort made to identify all literature relevant 
to this study. The evidence can be applied to settings similar to the ones in the included trials. 
None of these studies have however been conducted in developing countries.   
 
The evidence by way of literature review, statistical analysis and interpretation was of a good 
standard in all included articles and within the consulted meta-analyses referenced. Special care 
was taken to ensure high quality of studies included in order to obtain results that can be 
generalized to other populations. 
 
Although an extensive study was conducted, only studies in English were considered.  
Inter-observer agreement among study reviewers was satisfactory. Trials were independently 
reviewed and agreement was reached between the reviewers. The third reviewer was not called 
upon as all disagreements were resolved through discussion.  
 
Authors’ Conclusions: 
The need to conduct this review arose from considering the impact, complexities and the lack of 
proven preventative strategies for VAP. The results of this systematic review have the potential 
to provide guidance to nurses and other health care workers who are in the front line of the fight 
against nosocomial / hospital-acquired infections, allowing them to improve clinical practice.  
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Ventilator-associated pneumonia is a leading cause of death in hospitalized patients. Few studies 
have reported on nursing interventions to prevent VAP. The use of chlorhexidine in South Africa 
is not routine and needs to be studied in South African populations. Recent, reliable data and 
statistics relevant to developing countries, in particular South Africa, appear to be rare and 
unavailable. Allegranzi (2010:N.P.), at the World Health Organisation (WHO) inaugural 
infection control webinar series in 2010, emphasized that the lack of national policies, programs 
and guidelines together with a lack of data collection, monitoring and evaluation are constraints 
in Africa and in other developing countries . Reducing VAP may contribute to reducing the 
burden suffered by a health system that is struggling to cope with the burden of disease upon 
healthcare systems.   
 
Chlorhexidine in this review, proved to be beneficial for the prevention of ventilator-associated 
pneumonia. Results however need to be interpreted with the view of moderate heterogeneity. It is 
recommended that more studies be done on the optimal concentration, administration 
procedures, dosage and cost-effectiveness of chlorhexidine use as a focus of future more 
rigorously designed trials. Unlike the chlorhexidine effect on the incidence of VAP, evidence on 
mortality did not show any effect with the use of chlorhexidine. Chlorhexidine was found further 
to be a cost effective, safe treatment in the prevention of VAP. The use of 2% chlorhexidine may 
be more effective in reducing the incidence of VAP but due to the few trials that it was tested in, 
further research may be recommended. More evidence is needed from developing countries. 
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Figure 1:  Flow diagram of included studies 
 
 
 
 
Studies excluded due to failure to 
report outcomes as VAP (n=4) 
Studies retrieved for more 
detailed evaluation (n=15) 
Potentially appropriate studies to 
be included in the systematic 
review and meta-analysis (n=11) 
Studies included in systematic 
review (n=8) 
Studies excluded after critical 
appraisal of methodologies (n=3)  
 
MacNaughton (2004), full text not 
located                                            =1                                             
 
Grap (2004), attrition rate 50%     =1                                                                                               
 
Munro and Grap (2009), unsuccessful 
contacting authors                          =1     
Studies excluded                       (n=71) 
Non randomized trials                     51 
Non-oral chlorhexidine                     6 
Review                                              8 
Editorial or letter                               3 
Duplicate study                                 3 
 
Potentially relevant studies 
identified and screened for 
retrieval (n=86)  
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Table 1: Characteristics of included studies 
Study –Author, 
Year, study no. 
Population Intervention Comparison Chlorhexidine dosing 
schedule 
Loss to 
Follow-up 
DeRiso   1996  Cardio-
thoracic (open 
heart surgery) 
Chlorhexidine 
gluconate 
0.12%   
Placebo 0.5 ounces/15ml of 
Chlorhexidine 0.12% 
solution used as rinse pre-
operatively; twice daily 
post-operatively until 
discharge. 
None 
Fourrier   2000  Medical-
surgical ICU 
Chlorhexidine 
0.2% 
Standard oral 
care with 
bicarbonate 
isotonic 
serum rinse 
After mouth rinsing and 
oropharyngeal aspiration, 
gel  3 times a day during 
ICU stay 
None 
Fourrier   2005  Medical-
surgical ICU 
 
Chlorhexidine  
gluconate 0.2%  
Placebo Oral gel applied three 
times daily during ICU 
stay for 28days. 
One (0.87%) 
secondarily 
excluded 
(early 
antibiotics 
therapy)  
Houston 2002  Cardio-
thoracic (open 
heart surgery) 
Chlorhexidine 
gluconate 
0.12%  
Listerine 15 ml oral rinse post-
operatively and twice daily 
for 10days until death, 
extubation, tracheostomy 
or diagnosis of pneumonia. 
 
7.7% due to 
death and 
tracheostomy 
 
Koeman   2006  Mixed ICU’s Chlorhexidine 
2% 
 
Placebo Approximately 2cm of 
paste to buccal cavity, until 
VAP diagnosed death or 
extubation. 
1.55% due to 
consent:1 in 
placebo group 
and 2 in 
Chlorhexidine 
group 
 
Pobo  2009 
 
 
 
 
Medical-
surgical ICU 
Chlorhexidine 
digluconate 
0.12%  
Power Tooth- Gauze containing 20ml 
Chlorhexidine digluconate 
0.12% to all oral surfaces 
or 10ml Chlorhexidine 
injected into oral cavity, 
8hrly, for 28 days. Power 
tooth brushing 8hrly. 
2.7% Early 
introduction 
(<48hrs) of 
antibiotic since 
randomization.  
Scannapieco   
2009  
Trauma ICU Chlorhexidine 
gluconate  
0.12%  
Placebo Chlorhexidine 0.12% 
solution or Control twice 
daily as oral topical 
treatment, for up to 21 
days, until ICU discharge 
or death. 
16.57% 
secondary to 
death, 
tracheostomy. 
Tantipong  
2007  
ICU and 
general 
medical ward 
Chlorhexidine 
2% oral  
Normal 
Saline 
15 ml of Chlorhexidine 
solution or normal saline 4 
times per day until 
extubation. 
None 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
26 
 
Table 2: Methodological quality/ Risk of bias assessment 
Study –Author, 
Year,  
 
Adequate 
sequence 
generation 
Allocation 
Concealment 
Blinding of 
participants, 
personnel and 
outcome 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other Biases/ 
potential threats 
DeRiso 1996  
 
 
Low risk  
Computer-driven 
random number 
generated 
 
Low risk 
Randomization 
by the pharmacy. 
Low risk 
Placebo prepared    
and dispensed by 
pharmacy- 
placebo and 
treatment 
identical.  
Low risk  
All participants 
randomized  were 
analyzed  
Low risk 
All relevant 
outcomes fully 
reported on 
 
Low risk  
Nil noted 
 
Fourrier 2000  Low risk 
Computer –
generated 
balanced 
randomization 
table 
Low risk- 
blinded 
physicians in 
charge from 
results, dental 
bacteriologists 
from treatment 
allocation code, 
Low risk- 
hygiene nurse and 
physicians 
blinded to 
treatment given 
Low risk 
Intention to 
treat(ITT) 
Analysis  
reported  
Low risk 
All relevant 
outcomes fully 
reported on 
 
Low risk 
Nil noted 
 
Fourrier 2005  
 
Low risk 
Block 
randomization 
stratified by site  
Low risk 
 Randomization 
lists held in 
sealed envelopes 
in pharmacy. 
Low risk 
Investigators 
blinded to patient 
assignments.  
Low risk  
(ITT)analysis 
used-one 
Secondary 
exclusion. 
                                                          
Low risk  
All relevant 
outcomes fully 
reported on 
 
Low risk 
Nil noted 
 
Houston 2002 
 
 
High risk 
Consecutively 
randomized by 
medical record 
numbers 
Unclear Unclear Low risk 
All outcomes 
fully reported on 
Low risk 
All relevant 
outcomes fully 
reported on 
 
Unclear 
Koeman 2006   
 
 
Low risk   
Randomly 
assigned by 
computerized 
randomization 
stratified by 
hospital/ centre 
Low risk   
Experimental and 
placebo pastes 
produced and 
labeled by clinical 
pharmacy.  
Low risk   
Intensivists 
blinded to trail 
randomization. 
Low risk   
ITT employed; 
exclusions were 
low due  
Low risk   
 All relevant 
outcomes fully 
reported on 
  
Low risk    
Nil noted 
                                                      
Pobo   2009   
 
Low risk                                                                
Randomization  
by computer-
generated list 
Low risk                                    
Randomized by 
means of opaque 
sealed envelopes  
Low risk                                    
Investigators and 
attending 
physicians blind 
to group 
assignment. 
Low risk  All 
participants 
randomized  were 
analyzed                                                         
Low risk  
   
All relevant 
outcomes fully
reported on 
 
  
High risk    
Trial prematurely 
stopped by 
steering 
committee                                                           
Scannapieco 2009    
 
 
Low risk                                                               
Randomized by 
web-based 
subject 
enrollment 
system with 
protocol 
specification files 
Low risk                                    
Web-based 
(computer 
generated) 
randomization 
preparing 
individual 
treatment 
assignments by 
Low risk                                    
Assignment of 
treatments 
blinded to 
outcome 
assessors, 
statisticians and 
care providers.  
Low risk
ITT analysis 
employed                                                        
Low risk  
All relevant 
outcomes fully
reported on 
 
Low risk  Nil 
noted                                                          
Tantipong  2007     
 
Low risk 
Stratified 
randomization 
according to sex 
and  hospital 
location 
Low risk 
Executed by 
pharmacy. 
Low risk 
Blinding of data 
collectors and 
outcome 
assessors. 
Low risk     
All outcomes 
reported on.                                                           
Low risk   
All relevant 
outcomes fully
reported on 
                                                             
Low risk    
Nil noted                                                         
 
                              *Unclear = lack of information or unknown risk of bias 
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Figure 2- Random effects analysis: Risk of Ventilator-Associated Pneumonia (VAP) 
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Figure 3: Subgroup analysis of ventilator-associated pneumonia (VAP) per chlorhexidine 
level of therapeutic concentration 
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Figure 4: Random effects analysis –overall effect of chlorhexidine on mortality. 
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APPENDICES 
 
Appendix 1  
List of included studies: 
 
DeRiso, A.J., Ladowski, J.S., Dillon, T.A., Justice, J.W. & Peterson, A.C. 1996, "Chlorhexidine 
gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection 
and nonprophylactic systemic antibiotic use in patients undergoing heart surgery", Chest, 
vol. 109, no. 6, pp. 1556.  
 
Fourrier, F., Dubois, D., Pronnier, P., Herbecq, P., Leroy, O., Desmettre, T., Pottier-Cau, E., 
Boutigny, H., Di Pompéo, C. & Durocher, A. 2005, "Effect of gingival and dental plaque 
antiseptic decontamination on nosocomial infections acquired in the intensive care unit: A 
double-blind placebo-controlled multicenter study*", Critical Care Medicine, vol. 33, no. 8, 
pp. 1728.  
 
Fourrier, F., Duvivier, B., Boutigny, H., Roussel-Delvallez, M. & Chopin, C. 1998, 
"Colonization of dental plaque: a source of nosocomial infections in intensive care unit 
patients", Critical Care Medicine, vol. 26, no. 2, pp. 301.  
 
Houston, S., Hougland, P., Anderson, J.J., LaRocco, M., Kennedy, V. & Gentry, L.O. 2002, 
"Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of 
nosocomial pneumonia in patients undergoing heart surgery", American Journal of Critical 
Care, vol. 11, no. 6, pp. 567.  
 
Koeman, M., van der Ven, A.J.A.M., Hak, E., Joore, H.C.A., Kaasjager, K., de Smet, A.G.A., 
Ramsay, G., Dormans, T.P.J., Aarts, L.P.H.J. & de Bel, E.E. 2006, "Oral decontamination 
with chlorhexidine reduces the incidence of ventilator-associated pneumonia", American 
journal of respiratory and critical care medicine, vol. 173, no. 12, pp. 1348.  
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Pobo, A., Lisboa, T., Rodriguez, A., Sole, R., Magret, M., Trefler, S., Gómez, F. & Rello, J. 
2009, "A randomized trial of dental brushing for preventing ventilator-associated 
pneumonia", Chest, vol. 136, no. 2, pp. 433.  
Scannapieco, F., Yu, J., Raghavendran, K., Vacanti, A., Owens, S., Wood, K. & Mylotte, J. 
2009, "A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in 
mechanically ventilated patients", Critical Care, vol. 13, no. 4, pp. R117.  
 
Tantipong, H., Morkchareonpong, C., Jaiyindee, S. & Thamlikitkul, V. 2008, "Randomized 
controlled trial and meta-analysis of oral decontamination with 2% chlorhexidine solution 
for the prevention of ventilator-associated pneumonia", infection control and hospital 
epidemiology, vol. 29, no. 2, pp. 131-136.  
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Appendix 2 
List of excluded studies: 
 
Grap, M.J., Munro, C.L. & Elswick, R. 2004, "Duration of action of a single, early oral 
application of chlorhexidine on oral microbial flora in mechanically ventilated patients: a 
pilot study", Heart & Lung: The Journal of Acute and Critical Care, vol. 33, no. 2, pp. 83-
91.  
 
Munro, C.L., Grap, M.J., Jones, D.J., McClish, D.K. & Sessler, C.N. 2009, "Chlorhexidine, 
toothbrushing, and preventing ventilator-associated pneumonia in critically ill adults", 
American journal of critical care, vol. 18, no. 5, pp. 428.  
 
MacNaughton, P., Bailey, J., Donlin, N., Branfield, P., Williams, A. & Rowswell, H. 2004, "A 
randomized controlled trial assessing efficacy of oral chlorhexidine in ventilated patients", 
European Society of Intensive Care Medicine, 17th Annual Congress, Berlin, Germany. 
Intensive Care Med, pp. S5.  
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Appendix 3 
Data Extraction Forms 
 
Data extraction form 01  
1. Source 
Study ID 01 
Reviewer Olivia Snyders; Oswell Khondowe 
Author & 
Year 
DeRiso, A.J., Ladowski, J.S., Dillon, T.A., Justice, J.W. & Peterson, A.C.  
1996  
Journal Chest, vol. 109, no. 6, pp. 1556. 
Title "Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total 
nosocomial respiratory infection and nonprophylactic systemic antibiotic use in 
patients undergoing heart surgery" 
Country Indiana, USA 
 
2. Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental 
- 
Other specify - 
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Placebo   
Chlorexidine Vs Standard Care -  
 
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
 
2.5 Lost to follow up <15% 
Equation N/A  Y N 
 
 
2.5.1 Reasons for LTFU 
N/A 
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2.5.2 Other reasons for exclusion 
Intra-operative death; pre-operative infection or intubation; heart and lung transplant recipients;  
Pregnancy; known hypersensitivity to chlorhexidine;  
Concurrent participation in another research project;  
 
 
 
3. Methodology 
3.1 Study design 
RCT   Single centre   
Quasi-experimental - Multi centre - 
 
3.2 Study duration 
Month & Year 10 months –no dates provided 
 
 
3.3 Eligibility criteria 
Adults (> 18yrs); Consent obtained;  
Coronary artery bypass grafting (CABG), valve surgery, septal surgery, cardiac tumour excision,  
combined CABG and valve surgery requiring cardiopulmonary bypass,  
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
YES Computer-driven random number generated 
Allocation concealment? YES Randomization by the pharmacy staff. 
Blinding of participants, 
personnel and outcome 
assessors? 
YES Described only as a double-blind, placebo-controlled study. 
Incomplete outcome data 
addressed? 
YES All outcomes reported on  
Free of selective outcome 
reporting? 
YES 
- 
Free of other bias? YES - 
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 3.5 Participants 
Total number 353 
Total number analized 353 
Number of VAP cases 12 
Mortality 12 
High risk? No 
Setting Cardio-thoracic ICU 
Diagnostic criteria New or progressive pulmonary infiltrate, fever, 
leukocytosis, purulent tracheal secretions. 
Age  Mean 64yrs (male); mean 63 yrs (female) 
Sex M=  242         ; F = 111 
Country USA 
Date of study 1996 
*Mean±SD. 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
Chlorhexidine 
Gluconate 0.12% 
Oral , rinse 15ml rinse 
 
pre-operatively; twice 
daily post- operatively 
until discharge 
none 
Control group 
Type Route Dose Timing Side effect 
Placebo Oral, rinse 15ml rinse 
 
pre-operatively; twice 
daily post- operatively 
until discharge 
none 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
1. Incidence of Ventilator Associated Pneumonia YES  
2. Mortality YES  
 
3.8 Outcome definitions 
1. Incidence of Ventilator Associated Pneumonia YES    
2. Mortality YES   
 
 
4. Results 
Number of patients:    353 
 Randomized Analyzed 
Experimental 173 173 
Control 180 180 
Total 353 353 
 
4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group  3 170 173 
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Control group 9 164 173 
1. Mortality Event No event Total 
Experimental group  2 171 173 
Control group 10 163 173 
 
4.2 Continuous Data : N/A 
 
 
 
4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus Control group 0.35 0.10 – 1.26 0.18 
1. Mortality RR CI 95%  P-value 
Experimental group versus Control group 0.21 0.05 – 0.94 0.18 
 
 
4.4 Subgroup analysis 
Concentration: 0.12% chlorhexidine gluconate 
Settings: Cardiothoracic ICU 
 
 
4.5 Miscellaneous 
Funding source Grant:August Tomusk Foundation, Indiana 
Key conclusions Chlorhexidine decreases total respiratory infection rate 
and need for non-prophylactic antibiotic use in patients 
undergoing heart surgery; Cost saving; impacts 
favourably on mortality 
Other comments from authors Ease of administration 
Reference to other relevant studies YES     
Correspondence required X 
Comments from reviewers 
- 
1. Subgroup analysis needed-concentration 2. Study older than 10 years but part of review and not 
literature review, feasible. 
3. Setting favourable for positive effect=+-subanalysis 4. 
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Data extraction form 02 
1. Source 
Study ID 02 
Reviewer Olivia Snyders and Oswell Khondowe 
Author & 
Year 
Fourrier, F., Duvivier, B., Boutigny, H., Roussel-Delvallez, M. & Chopin, C. 
1998,  
Journal Critical Care Medicine, vol. 26, no. 2, pp. 301.  
 
Title "Colonization of dental plaque: a source of nosocomial infections in intensive 
care unit patients" 
Country France 
 
2. Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental  
Other specify  
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Bicarbonate rinse   
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
2.5 Lost to follow up <15% 
Equation None  N 
 
2.5.1 Reasons for LTFU 
No LTFU 
 
 
2.5.2 Other reasons for exclusion 
Edentulous Patients; <18yrs;  
No consent;  
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3. Methodology 
3.1 Study design 
RCT   Single centre   
Quasi-experimental  Multi centre  
 
3.2 Study duration 
Month & Year June 1997 to July 1998 
 
3.3 Eligibility criteria 
>18yrs; Consent 
Medical condition suggest ICU stay of 5 days requiring mechanical ventilation 
 
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
Yes Computer –generated balanced randomization table 
Allocation concealment? Yes Blinded physicians in charge from results, dental 
bacteriologists 
Blinding of participants, 
personnel and outcome 
assessors? 
Yes Hygiene nurse and physicians blinded to treatment given 
Incomplete outcome data 
addressed? 
Yes Intention to treat(ITT) 
Analysis  reported; All outcomes addressed 
Free of selective outcome 
reporting? 
Yes No evidence of publication bias 
Free of other bias? Yes -- 
 
       3.5 Participants 
Total number 60 
Total number analized 60 
Number of VAP cases 20 
Mortality 10 
High risk? no 
Setting Medical-surgical ICU 
Diagnostic criteria Temperature>38˚C or < 36˚C; presence of infiltrate on 
chest radiography; leukocytosis or leucopenia;positive 
quantitative culture of tracheal aspirate(10⁶CFU/ml) 
and/or positive culture of BAL (10⁶CFU/ml). 
Age  Treatment mean=51.2; Control mean=50.4 
Sex Treatment (m/f)= 19/11; Control (m/f)= 1911 
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Country France 
Date of study June 1997-July 1998 
*Mean±SD. 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
Chlorhexidine 
0.2% dental gel 
Oral-
oropharyngeal 
surfaces 
- 3x day none 
Control group 
Type Route Dose Timing Side effect 
Bicarbonate 
isotonic serum 
Oral rinse - 4xday none 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
3. Incidence of Ventilator Associated Pneumonia YES  
4. Mortality YES  
 
3.8 Outcome definitions 
3. Incidence of Ventilator Associated Pneumonia YES  
4. Mortality YES  
 
 
4. Results 
Number of patients:     60 
 Randomized Analyzed 
Experimental 30 30 
Control 30 30 
Total 60 60 
 
4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group 5 25 30 
Control group 15 15 30 
 
1. Mortality Event No event Total 
Experimental group 3 27 30 
Control group 7 23 30 
 
4.2 Continuous Data-N/A 
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4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus Control group 0.33 0.14 – 0.80  
1. Mortality RR CI 95%  P-value 
Experimental group versus Control group 0.43 0.12 – 1.50 0.18 
 
4.4 Subgroup analysis 
Chlorhexidine concentration 0.2%  
Setting- medical –surgical ICU 
 
 
4.5 Miscellaneous 
Funding source Not mentioned 
Key conclusions Antiseptic oral decontamination may reduce incidence 
of VAP 
Other comments from authors Results need further confirmation 
Reference to other relevant studies Yes 
Correspondence required No 
Comments from reviewers For inclusion 
1.ITT analysis performed 2. 
3. 4. 
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Data extraction form 03 
1. Source 
Study ID 03 
Reviewer Olivia Snyders and Oswell Khondowe 
Author & 
Year 
Fourrier, F., Dubois, D., Pronnier, P., Herbecq, P., Leroy, O., Desmettre, T., 
Pottier-Cau, E., Boutigny, H., Di Pompéo, C. & Durocher, A. 2005, ,  
Journal Critical Care Medicine, vol. 33, no. 8, pp. 1728.  
 
Title "Effect of gingival and dental plaque antiseptic decontamination on nosocomial 
infections acquired in the intensive care unit: A double-blind placebo-controlled 
multicenter study*" 
Country France 
 
2. Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental  
Other specify  
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Placebo   
Chlorexidine Vs Standard Care --- ---- 
 
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
2.5 Lost to follow up <15% 
Equation  Y  
 
2.5.1 Reasons for LTFU 
Secondary exclusion- oral antibiotic therapy required (n=1) 
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2.5.2 Other reasons for exclusion 
Tracheostomy at inclusion, 
Hospitalisation >48hrs 
Randomization after D0 (within 24hrs of randomization) 
Completely edentulous, facial trauma, post surgical patients with ‘specific oropharyngeal care” 
Known allergy to chlorhexidine 
 
 
 
3. Methodology 
3.1 Study design 
RCT   Single centre  
Quasi-experimental  Multi centre   
 
3.2 Study duration 
Month & Year Jan 2001-Sept 2002 
 
3.3 Eligibility criteria 
Adult > 18yrs and medical condition suggesting ICU stay at least 5days 
Requiring mechanical ventilation by orotrachela or nsao tracheal intubation 
Hospitalisation <48hrs 
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
Yes Block randomization stratified by site 
Allocation concealment? Yes Randomization lists held in sealed envelopes in pharmacy. 
Blinding of participants, 
personnel and outcome 
assessors? 
Yes Investigators blinded to patient assignments 
Incomplete outcome data 
addressed? 
Yes All outcomes reported on 
Free of selective outcome 
reporting? 
Yes No evidence of Publication Bias 
Free of other bias? Yes - 
 
       3.5 Participants 
Total number 228 
Total number analized 228 
Number of VAP cases 25 
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Mortality 55 
High risk? No 
Setting Multi-centre, mixed ICU population 
Diagnostic criteria Temperature>38˚C or < 36˚C; presence of infiltrate on 
chest radiography; leukocytosis or leucopenia;positive 
quantitative culture of tracheal aspirate(10⁶CFU/ml) 
and/or positive culture of BAL (10⁶CFU/ml). 
Age  Chlorhexidine mean age(61.1yrs); Placebo mean age 
(61 yrs) 
Sex PAD-(m)=72; (f)=41;        Placebo (m)=64; (f)=50 
Country France 
Date of study Jan 2001-September 2002 
*Mean±SD. 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
Chlorhexidine  
gluconate 0.2% 
Oral gel After mouth rinse 
and oro-paryngeal 
aspiration, gel 
applied 
3x daily during ICU 
stay and until 28days 
of treatment achieved. 
Nil reported 
Control group 
Type Route Dose Timing Side effect 
Placebo Oral gel After mouth rinse 
and oro-paryngeal 
aspiration, gel 
applied 
3x daily during ICU 
stay and until 28days 
of treatment achieved. 
Nil reported 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
5. Incidence of Ventilator Associated Pneumonia YES  
6. Mortality YES  
 
3.8 Outcome definitions 
5. Incidence of Ventilator Associated Pneumonia YES  
6. Mortality YES  
 
 
4. Results 
Number of patients:    228 
 Randomized Analyzed 
Experimental 114 113 
Control 114 114 
Total 228 227 
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4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group 13 101 114 
Control group 12 102 114 
 
1. Mortality Event No event Total 
Experimental group 31 83 114 
Control group 24 90 114 
 
4.2 Continuous Data –N/A 
 
4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus Control group 1.08 0.52- 2.27 0.18 
1. Mortality RR CI 95%  P-value 
Experimental group versus Control group 1.29 0.81 – 2.06 0.18 
 
4.4 Subgroup analysis 
Chlorhexidine concentration , 0.2% 
Multi-centre trial= Mixed ICU population 
 
 
4.5 Miscellaneous 
Funding source Supported in part by French Ministry of Health 
Key conclusions PAD prophylaxis insufficient in critically ill patients 
Other comments from authors PAD decrease rate of plaque colonization in ventilated 
patients (by aerobic pathogens) 
Reference to other relevant studies YES 
Correspondence required No 
Comments from reviewers For inclusion 
1. 2. 
3. 4. 
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Data extraction form 04 
1. Source 
Study ID 04 
Reviewer (OS) and (OK) 
Author & 
Year 
Houston, S., Hougland, P., Anderson, J.J., LaRocco, M., Kennedy, V. & 
Gentry, L.O. 2002, ,  
Journal American Journal of Critical Care, vol. 11, no. 6, pp. 567.  
Title "Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing 
prevalence of nosocomial pneumonia in patients undergoing heart surgery" 
Country Houston, Texas,USA 
 
2. Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental  
Other specify  
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Placebo   
Chlorexidine Vs Standard Care ---  
 
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
2.5 Lost to follow up <20% 
Equation 7.7% ------ Yes 
 
2.5.1 Reasons for LTFU 
Death and Tracheostomy 
 
2.5.2 Other reasons for exclusion 
Death during surgery; pregnancy; lack of consent 
Pre-op Respiratory Infection  
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3. Methodology 
3.1 Study design 
RCT   Single centre   
Quasi-experimental  Multi centre  
 
3.2 Study duration 
Month & Year Details not provided 
 
3.3 Eligibility criteria 
Adult, >18yrs 
Aorta-coronary bypass graft and valve surgery; cardiopulmonary surgery 
Consent 
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
No Consecutively randomized by medical record numbers-poor 
method 
Allocation concealment? Unclear No details provided 
Blinding of participants, 
personnel and outcome 
assessors? 
Unclear No details provided 
Incomplete outcome data 
addressed? 
Unclear All outcomes reported on 
Free of selective outcome 
reporting? 
Yes No publication bias 
Free of other bias? Yes Yes 
 
       3.5 Participants 
Total number 561 
Total number analized 561 
Number of VAP cases 13 
Mortality 9 
High risk? No 
Setting Cardio-thoracic (open heart surgery) 
Diagnostic criteria New or progressive infiltrate, CDC tool based on 
criteria for diagnosing nosocomial pneumonia: Fever 
and pulmonary infiltrate; nature of trachea-bronchial 
secretions; degree of leukocytosis; microbial culture 
results. Semi-quantitative sputum samples at 
extubation. 
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Age  Not provided 
Sex Exp Group-(m)=73,(f)=197  ;Comparison-(m)=79, 
(f)=212 
Country Houston, Texas 
Date of study 2002 
*Mean±SD. 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
Chlorhexidine 
gluconate 0.12% 
Oral Rinse 15 ml oral rinse post-
operatively  
twice daily for 10days 
until death, 
extubation, 
tracheostomy or 
diagnosis of 
pneumonia. 
None 
Control group 
Type Route Dose Timing Side effect 
Listerine Oral Rinse 15 ml oral rinse post-
operatively 
As above None 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
7. Incidence of Ventilator Associated Pneumonia YES  
8. Mortality YES  
 
3.8 Outcome definitions 
7. Incidence of Ventilator Associated Pneumonia YES  
8. Mortality YES  
 
 
4. Results 
Number of patients:  561 
 Randomized Analyzed 
Experimental 270 270 
Control 291 291 
Total 561 561 
 
4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group 4 266 270 
Control group 9 282 291 
 
1. Mortality Event No event Total 
Experimental group 6 264 270 
Control group 3 288 291 
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4.2 Continuous Data –(none) 
 
4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus Control group 0.48 0.15 - 1.54 0.18 
1. Mortality RR CI 95%  P-value 
Experimental group versus Control group 2.16 0.54-8.53 0.18 
 
4.4 Subgroup analysis 
Setting: Cardiothoracic 
0.12% chlorhexidine 
 
 
 
4.5 Miscellaneous 
Funding source Roderick McDonald Fund, Houston, Texas 
Key conclusions Nosocomial infections lower in peridex group 
Other comments from authors Peridex group effect only significant in patients 
intubated >24hours 
Reference to other relevant studies YES 
Correspondence required Possibly 
Comments from reviewers Included in other meta-analyses 
1.Follow methodology 2. 
3. 4. 
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Data extraction form 05 
1. Source 
Study ID 05 
Reviewer Olivia Snyders and Oswell Khondowe 
Author & 
Year 
Koeman, M., van der Ven, A.J.A.M., Hak, E., Joore, H.C.A., Kaasjager, K., de 
Smet, A.G.A., Ramsay, G., Dormans, T.P.J., Aarts, L.P.H.J. & de Bel, E.E. 
2006 
Journal American journal of respiratory and critical care medicine, vol. 173, no. 12, 
pp. 1348. 
Title "Oral decontamination with chlorhexidine reduces the incidence of ventilator-
associated pneumonia" 
Country Netherlands 
 
2. Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental  
Other specify  
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Placebo   
Chlorexidine Vs Standard Care   
 
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
2.5 Lost to follow up <20% 
Equation 1.55% Y  
 
2.5.1 Reasons for LTFU 
Consent Withdrawal  : Treatment group (n=2);  Comparison Group (n=1) 
 
 
 
2.5.2 Other reasons for exclusion 
Pre-admission immunocompromised status 
Pregnant;  
Stellenbosch University  http://scholar.sun.ac.za
51 
 
Pre-existing condition not allowing oral application of study medication; 
 
3. Methodology 
3.1 Study design 
RCT   Single centre  
Quasi-experimental  Multi centre   
 
3.2 Study duration 
Month & Year unknown 
 
3.3 Eligibility criteria 
Adult ( >18yrs) 
Need for mechanical ventilation at least 48hrs 
Inclusion within 24hrs of intubation and start of mechanical ventilation 
 
 
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
Yes Randomly assigned by computerized randomization 
Allocation concealment? Yes Experimental and placebo pastes produced and labeled by 
clinical 
Blinding of participants, 
personnel and outcome 
assessors? 
Yes Experimental and Placebo pastes prepared and labeled by 
clinical pharmacy 
Incomplete outcome data 
addressed? 
Yes ITT employed; exclusions were low due, Full outcome 
data provided 
Free of selective outcome 
reporting? 
Yes No evidence of publication bias 
Free of other bias? Yes ---- 
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       3.5 Participants 
Total number 257 
Total number analized 257 
Number of VAP cases 36 
Mortality 88 
High risk? 88 
Setting ICU, mixed, multi-centre 
Diagnostic criteria Chest radiography with new, persistent or progressive 
infiltrate in combination with at least 3 of 4 of the 
following criteria: Temperature>38 ˚C or < 35.5˚C; 
Blood Leukocytosis or leucopenia; purulent tracheal 
aspirate; positive semi-quantitative culture from 
tracheal aspirates (cutoff≥10⁵cfu/ml).  
Daily Clinical Pulmonary Infection Scores (CPIS) 
were done. 
Age  Chlorhexidine mean=60.9,Placebo mean=62.1 
Sex Chlorhexidine (m)=66,(f)=61; Placebo(m)=93, (f)=37 
Country Netherlands 
Date of study Feb 2001-March 2003 
*Mean±SD. 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
Chlorhexidine 
2% 
Oral-buccal 
cavity 
Approximately 2cm 
of paste (0.5gram) 
administered to each 
side of buccal cavity. 
Study stopped when 
VAP diagnosed, 
death, consent 
withdrawal or 
extubation. 
None 
Control group 
Type Route Dose Timing Side effect 
Placebo Oral-buccal 
cavity 
Approximately 2cm 
of paste (0.5gram) 
administered to each 
side of buccal cavity. 
Study stopped when 
VAP diagnosed, 
death, consent 
withdrawal or 
extubation. 
None 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
9. Incidence of Ventilator Associated Pneumonia YES  
10. Mortality YES  
 
3.8 Outcome definitions 
9. Incidence of Ventilator Associated Pneumonia YES  
10. Mortality YES  
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4. Results 
Number of patients:    257 
 Randomized Analyzed 
Experimental 127 127 
Control 130 130 
Total 257 257 
 
4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group 13 114 127 
Control group 23 107 130 
 
1. Mortality Event No event Total 
Experimental group 49 78 127 
Control group 39 91 130 
 
4.2 Continuous Data- None 
 
4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus Control group 0.58 0.31 – 1.09 0.18 
1. Mortality RR CI 95%  P-value 
Experimental group 1.29  0.91 – 1.81 0.18 
 
4.4 Subgroup analysis 
Concentration -2% Chlorhexidine  
Settings –mixed ICU 
4.5 Miscellaneous 
Funding source Not mentioned 
Key conclusions Topical and oral use of Chlorhexidine and Colistin 
reduced VAP 
Other comments from authors Chlorhexidine probably the preferred preventative 
strategy of choice 
Reference to other relevant studies YES 
Correspondence required NO 
Comments from reviewers For inclusion 
1.ITT employed 2. 
3. 4. 
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Data extraction form 06 
1. Source 
Study ID 06 
Reviewer Olivia Snyders and Oswell Khondowe 
Author & 
Year 
Pobo, A., Lisboa, T., Rodriguez, A., Sole, R., Magret, M., Trefler, S., Gómez, 
F. & Rello, J. 2009  
 
Journal Chest, vol. 136, no. 2, pp. 433 
Title "A randomized trial of dental brushing for preventing ventilator-associated 
pneumonia" 
Country Spain 
 
2. Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental  
Other specify  
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Power 
Toothbrushing 
  
 
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
2.5 Lost to follow up <15% 
Equation 2.7% Y  
 
2.5.1 Reasons for LTFU 
Early introduction of antibiotics within 48hrs of randomization 
 
 
2.5.2 Other reasons for exclusion 
Lack of consent; <18 years of age; Chlorhexidine allergy; 
Suspicion of Pneumonia at time of intubation; Evidence of massive aspiration during intubation; 
Tracheostomy; Intubated patients; moribund patients(expected to die within 72hrs) 
Edentulous patients; Pregnancy; 
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Enrollment in other trials  
3. Methodology 
3.1 Study design 
RCT   Single centre   
Quasi-experimental  Multi centre  
 
3.2 Study duration 
Month & Year  
 
3.3 Eligibility criteria 
>18yrs, Consent 
Intubation expected within 48hrs of randomization;  
No evidence of Pulmonary infection 
 
 
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
Yes Randomization  by computer-generated list 
Allocation concealment? Yes Randomized by means of opaque sealed envelopes 
Blinding of participants, 
personnel and outcome 
assessors? 
Yes Investigators and attending physicians blind to group 
assignment. 
Incomplete outcome data 
addressed? 
Yes All participants randomized  were analyzed  ; All relevant 
outcomes reported on                                                                   
Free of selective outcome 
reporting? 
Yes No evidence of Publication Bias 
Free of other bias? No Trial prematurely stopped by steering committee                                                           
 
       3.5 Participants 
Total number 147 
Total number analized 143 
Number of VAP cases 33 
Mortality 39 
High risk? Yes 
Setting Medical-surgical ICU 
Diagnostic criteria Presence of new or progressive pulmonary opacities 
on chest radiography, purulent respiratory secretions, 
fever (>38˚C), Leukocytosis > 10,000cells/ml, 
quantitative respiratory samples with at least one 
pathogenic organism (protected specimen brush 
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yielding ≥ 103 or tracheal aspirates yielding 
10⁵cfu/mL). 
Age  Std group: mean age52.6  TBgroup: mean=55.3 
Sex Std group(m)=46,(f)=;27   TBrushing (m)=49,(f)=25 
Country Spain 
Date of study Unknown; 30month period 
*Mean±SD. 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
Power 
Toothbrushing 
Oral Use of Power 
Toothbrush 
8hrly None 
Control group 
Type Route Dose Timing Side effect 
Standard care with 
chlorhexidine 
Oral 20ml Chlorhexidine 
to oral surfaces 
8hrly None 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
11. Incidence of Ventilator Associated Pneumonia YES  
12. Mortality YES  
 
3.8 Outcome definitions 
11. Incidence of Ventilator Associated Pneumonia YES  
12. Mortality YES  
 
 
4. Results 
Number of patients:    147 
 Randomized Analyzed 
Experimental 74 70 
Control 73 73 
Total 147 143 
 
4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group 15 55 70 
Control group 18 55 73 
 
1. Mortality Event No event Total 
Experimental group 16 54 70 
Control group 23 50 73 
 
 
 
4.2 Continuous Data-None 
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4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus  Control group 1.22 0.66 – 2.23 0.18 
1. Mortality RR CI 95%  P-value 
Experimental group versus  Control group 1.46 0.84 – 2.53 0.18 
 
4.4 Subgroup analysis 
Chlorhexidine concentration, 0.12% 
Setting-mixed icu 
 
 
4.5 Miscellaneous 
Funding source Not mentioned 
Key conclusions Addition of mechanical debridement system to the use 
of chlorhexidine to prevent VAP not effective 
Other comments from authors Larger groups needed 
Reference to other relevant studies Yes 
Correspondence required No 
Comments from reviewers Check mehtodology 
1. 2. 
3. 4. 
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Data extraction form 7 
1. Source 
Study ID 07 
Reviewer Olivia and Oswell 
Author & 
Year 
Scannapieco, F., Yu, J., Raghavendran, K., Vacanti, A., Owens, S., Wood, K. & 
Mylotte, J. 2009 
 
Journal Critical Care, vol. 13, no. 4, pp. R117. 
Title "A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in 
mechanically ventilated patients" 
Country Eirie Country , Buffalo, USA 
 
2.Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental  
Other specify  
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Placebo   
Chlorexidine Vs Standard Care ----  
 
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
2.5 Lost to follow up <15% 
Equation 16.57 % Y  
 
2.5.1 Reasons for LTFU 
Death or  tracheostomy. 
 
 
2.5.2 Other reasons for exclusion 
Known sensitivity to Chlorhexidine; Pregnancy; <18yrs; legal incarceration; Oral mucocytosis 
Immunosuppression; transfer from another ICU ; Re-admission to ICU; “Do not Intubate” Order 
No consent; Diagnosis of Thrombocytopenia; Confirmed diagnosis of of ost obstructive 
pneumonia; witnessed aspiration; intubation > 48hrs since admission 
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3. Methodology 
3.1 Study design 
RCT   Single centre   
Quasi-experimental  Multi centre  
 
3.2 Study duration 
Month & Year 2009 (March 2004-November 2007) 
 
3.3 Eligibility criteria 
>18years, Consent ; expected intubation within 48hrs from admission;  
 
 
 
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
Yes Randomized by web-based subject enrollment 
Allocation concealment? Yes Web-based (computer generated) randomization 
Blinding of participants, 
personnel and outcome 
assessors? 
Yes Assignment of treatments blinded to outcome assessors 
Incomplete outcome data 
addressed? 
Yes Outcomes fully reported on.                                                               
Free of selective outcome 
reporting? 
Yes No evidence of reporting bias 
Free of other bias? Yes ------ 
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Participants 
Total number 117 
Total number analized 117 
Number of VAP cases 19 
Mortality 16 
High risk? No 
Setting Trauma ICU 
Diagnostic criteria CPIS scores based on following elements: Partial 
pressure of arterial oxygenation (PaO²)/Fraction of 
inspired oxygen (FiO²), Infiltrate on chest radiology, 
fever, leukocytosis and purulent secretions. CPIS 
scores or 6 or more triggered BAL sampling of lower 
airways. 
Age  Exp Mean (age)=50.0; Comp Mean(age)=47.6 
Sex (M) = 80         ;(F)= 37 
Country USA 
Date of study 2009 (March 2004-November 2007) 
*Mean±SD. 
 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
Chlorhexidine 0.12 
% solution  
Oral rinse 
(solution) 
 
2x daily as oral 
topical treatment with 
patients followed for 
up to 21 days, until 
discharge from ICU 
or  death 
None 
Control group 
Type Route Dose Timing Side effect 
Placebo Oral rinse 
(solution) 
 
2x daily as oral 
topical treatment with 
patients followed for 
up to 21 days, until 
discharge from ICU 
or  death 
None 
 
 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
13. Incidence of Ventilator Associated Pneumonia YES  
14. Mortality YES  
 
3.8 Outcome definitions 
13. Incidence of Ventilator Associated Pneumonia YES  
14. Mortality YES  
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4. Results 
Number of patients:    117 
 Randomized Analyzed 
Experimental 58 58 
Control 59 59 
Total 117 117 
 
4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group 7 110 117 
Control group 12 105 117 
 
1. Mortality Event No event Total 
Experimental group 8 109 117 
Control group 8 109 117 
 
4.2 Continuous Data- N/A 
 
4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus Control group 0.59 0.25 – 1.40 0.18 
1. Mortality RR CI 95%  P-value 
Experimental group versus Control group 1.02 0.41 – 2.53 0.18 
 
4.4 Subgroup analysis 
Concentration- 0.12% chlorhexidine 
Setting- Trauma ICU (mixed) 
 
 
4.5 Miscellaneous 
Funding source USPH grant –national institute of dental and craniofacial 
surgery 
Key conclusions Chlorhexidine did not reduce the total# of potential 
respiratory pathogensbut did reduce  the # of Staph 
aureas in dental plaqueof trauma ICU patients 
Other comments from authors none 
Reference to other relevant studies Yes, prev meta-analyses  
Correspondence required No 
Comments from reviewers For inclusion 
1. ITT analysis  2. 
3. 4. 
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Data extraction form 08 
1. Source 
Study ID 08 
Reviewer Olivia Snyders and Oswell Khondowe 
Author & 
Year 
Tantipong, H., Morkchareonpong, C., Jaiyindee, S. & Thamlikitkul, V. 2008,  
Journal Infection control and hospital epidemiology, vol. 29, no. 2, pp. 131-136.  
 
Title "Randomized controlled trial and meta-analysis of oral decontamination with 
2% chlorhexidine solution for the prevention of ventilator-associated 
pneumonia" 
Country Bangkok, Thailand 
 
2. Eligibilty  
(Tick in the appropriate space) 
2.1 Types of studies 
RCT   
Quasi-experimental  
Other specify  
Published study   
 
2.2 Types of participants 
Adult Ventilated Patients    
 
2.3 Types of intervention 
(Tick appropriate intervention provide details on other treatment in space provided) 
Chlorexidine vs Normal Saline   
Chlorhexidine vs Placebo   
 
2.4 Types of outcomes 
Incidence of VAP   
Mortality   
 
2.5 Lost to follow up <15% 
Equation ----- N - 
 
2.5.1 Reasons for LTFU 
None 
 
 
2.5.2 Other reasons for exclusion 
Diagnosis / presence of pneumonia on admission 
Chlorhexidine sensitivity 
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3. Methodology 
3.1 Study design 
RCT   Single centre   
Quasi-experimental  Multi centre  
 
3.2 Study duration 
Month & Year  
 
3.3 Eligibility criteria 
Adult (>18yrs); Mechanically ventilated hospitalized in ICU; 
 
 
Methodological quality/Risk of bias assessment 
(Answer the domain-question with a ‘Yes’ signifying low risk of bias, ‘No’ signifying high risk of 
bias, and ‘Unclear’ signifying either lack of information or unknown risk of bias) 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool 
Entry Judgement Description 
Adequate sequence 
generation? 
Yes Stratified randomization according to sex and hospital 
location 
Allocation concealment? Yes Executed by pharmacy staff 
Blinding of participants, 
personnel and outcome 
assessors? 
Yes Blinding of to data collectors and outcome assessors. 
Incomplete outcome data 
addressed? 
Yes All outcomes addressed 
Free of selective outcome 
reporting? 
Yes All outcomes reported on 
Free of other bias? Yes - 
 
3.5 Participants 
Total number 207 
Total number analized 207 
Number of VAP cases 17 
Mortality 73 
High risk? NO 
Setting ICU-mixed 
Diagnostic criteria Chest radiography with new, persistent or progressive 
infiltrate in combination with at least 3 of the 
following criteria: Temperature > 38˚C or < 35.5˚C, 
leukocytosis or leucopenia, purulent tracheal aspirate, 
tracheal aspirate and/or a semi-quantitative sample of 
tracheal aspirate which was positive for pathogenic 
bacteria. 
Age  Mean :(treatment)=56.5;(Nacl)=60.3 
Sex Male: 101  Female: 106 
Country Bangkok, Thailand 
Date of study Jan 2006-March 2007 
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*Mean±SD. 
3.6 Interventions 
Experimental group 
Type Route Dose Timing Side effect 
2% 
Chlorhexidine  
Oral  15ml oral rinse plus 
toothbrushing 
4xday Irritation of the 
oral mucosa 
(n=10) 
Control group 
Type Route Dose Timing Side effect 
Normal Saline oral oral rinse plus 
toothbrushing 
4xday Irritation of the 
oral mucosa 
(n=1) 
 
3.7 Outcomes relevant to this review 
(Tick yes or no) 
1. Incidence of Ventilator Associated Pneumonia YES  
2. Mortality YES  
 
3.8 Outcome definitions 
1. Incidence of Ventilator Associated Pneumonia YES  
2. Mortality YES  
 
 
4. Results 
Number of patients:    207 
 Randomized Analyzed 
Experimental 102 102 
Control 105 105 
Total 207 207 
 
4.1 Summary data for each intervention group 
1. Incidence of VAP Event No event Total 
Experimental group 5 97 102 
Control group 12 93 105 
 
1. Mortality Event No event Total 
Experimental group 36 66 102 
Control group 37 68 105 
 
 
4.2 Continuous Data- N/A 
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4.3 Estimate of effect with confidence interval/P-value 
1. Incidence of VAP RR CI 95%  P-value 
Experimental group versus Control group 0.43 0.16 – 1.17 0.18 
1. Mortality RR CI 95%  P-value 
Experimental group versus Control group 1.00 0.69 – 1.45 0.18 
 
 
4.4 Subgroup analysis 
Chlorhexidine concentration (2% used) 
Trial setting (mixed ICU) 
 
 
4.5 Miscellaneous 
Funding source Thailand research funding & faculty of medicine Siriraj 
Hospital Thailand 
Key conclusions 2% chlorhexidine cost effective strategy to reduce risk 
of VAP 
Other comments from authors No diff in duration of MV  or LOS in ICU or mortality 
Reference to other relevant studies Koeman et al 2002; chlebicki et al (2007); chan et al 
(2007); Kola et al(2007); 
Correspondence required No 
Comments from reviewers Meta-analysis embedded in article 
1. 2. 
3. 4. 
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